MedTrace Logo

Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19

NCT04261517 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-04-13

No results posted yet for this study

Summary

The study aims to evaluate the efficacy and safety of hydroxychloroquine in the treatment of COVID-19 pneumonia.

Conditions

  • Pneumonia, Pneumocystis
  • Coronavirus
  • COVID-19

Interventions

DRUG

Hydroxychloroquine

Subjects take hydroxychloroquine 400 mg per day for 5 days, also take conventional treatments

Sponsors & Collaborators

  • Shanghai Public Health Clinical Center

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-06
Primary Completion
2020-02-25
Completion
2020-02-25

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04261517 on ClinicalTrials.gov